阿罗洛尔治疗肝硬化患者门静脉高压的疗效观察

Therapeutic effect of Haro Carol on portal hypertension in patients with liver cirrhosis

[目的]研究阿罗洛尔治疗肝硬化患者门静脉高压的临床疗效。[方法]研究对象选取济南军区总医院2015年10月~2016年12月间收治的肝硬化伴门静脉高压患者102例,采用随机数字法将其分为对照组和观察组,每组各51例。对照组患者给予普萘洛尔治疗,观察组患者给予阿罗洛尔治疗。比较2组患者治疗前后的门静脉和脾静脉血流量、肝功能指标及血流动力学指标,同时比较不良反应发生率。[结果]治疗后,观察组的门静脉和脾静脉血流量均明显低于对照组(P<0.01),TBiL、ALB及ALT值均明显低于对照组(P<0.01),HVPG、WHVP均明显低于对照组(P<0.01),FHVP比较差异无统计学意义;2组患者的不良反应发生率比较差异无统计学意义。[结论]阿罗洛尔治疗肝硬化门静脉高压患者的临床疗效显著,可明显降低门静脉及脾静脉血流量,改善患者血流动力学,促进肝脏功能恢复,且治疗安全性较高,值得在临床推广。

[Objective]To study the clinical efficacy of Haro Carol on portal hypertension in patients with liver cirrhosis.[Methods]The subjects were 102 cases of patients with liver cirrhosis and portal hypertension in our hospital from October 2015 to December 2016,who were randomly divided into control group and observation group,51 cases in each group.The control group were treated with propranolol,and the observation group were given the Haro Carol.Before and after treatment,portal vein and splenic vein blood flow,dynamic indexes of hepatic function and blood flow were compared between the two groups.The incidence of adverse reactions were observed.[Results]After the treatment,the blood flow of the portal vein and splenic vein in observation group was significantly lower than the control group（P〈0.01）,TBIL,ALB and ALT values were significantly lower than the control group（P〈0.01）,HVPG,WHVP and FHVP were significantly lower than the control group（P〈0.01）.There was no significant difference in FHVP.There was no significant difference in adverse reaction rate between the two groups.[Conclusion]There was significant clinical curative effect of Haro Carol on cirrhosis of the liver.It can significantly reduce the blood flow of portal vein and splenic vein,improve hemodynamics,promote liver function recovery with high safety,which is worthy of promotion.